The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V):

##STR00001##

##STR00002##

and salts thereof, wherein R.sup.1, R.sup.2, A, and X.sub.10-X.sub.19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.

The present invention relates to a composition comprising a compound of formula (H1) and a compound of formula (H2). The present invention furthermore relates to a formulation comprising a composition comprising a compound of formula (H1) and a formula (H2) and a solvent. Finally, the present invention relates to an electronic device comprising a such a composition.

The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia

(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

Provided are compounds capable of functioning as an emitter in an organic light emitting device at room temperature, and the compounds are at least 40% deuterated. Also provided are their uses in OLED related electronic devices.

An organometallic compound, represented by Formula 1:

M.sub.1(Ln.sub.1).sub.n1(Ln.sub.2).sub.n2  Formula 1

wherein, in Formula 1, M.sub.1 is a transition metal, Ln.sub.1 is a ligand represented by Formula 1A, Ln.sub.2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2:

##STR00001##

wherein, in Formulae 1A, 1B, CY.sub.1, CY.sub.2, CY.sub.4, X.sub.1, X.sub.2, Y.sub.1, R.sub.1, R.sub.2, R.sub.10, R.sub.20, R.sub.40, R.sub.31, R.sub.32, R.sub.33, R.sub.34, R.sub.40, b10, b20, and b40 are as provided herein, and wherein * and * each indicate a binding site to M.sub.1.

A light emitting device includes a first electrode, a second electrode disposed on the first electrode, and at least one functional layer disposed between the first electrode and the second electrode. The at least one functional layer includes an amine compound represented by Formula 1. A light emitting device including the amine compound may show improved efficiency and life characteristics.

##STR00001##

A compound represented by the following formula (1) (In the formula (1), at least one of R.sub.1 to R.sub.8 is a deuterium atom; Ar.sub.2 is a monovalent group represented by the following formula (2), (3) or (4)).

##STR00001##

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT.sub.2 receptor.

##STR00001##

A light-emitting device including an organometallic compound represented by Formula 1, an electronic apparatus including the light-emitting device, and the organometallic compound represented by Formula 1 are provided.

##STR00001##

A light emitting element includes a polycyclic compound having a B-N-B structure and including a specific substituent in an emission layer, thereby showing high efficiency and long-life characteristics.